Abstract |
To evaluate the efficacy of adjunctive aripiprazole in patients with minimal response to prior antidepressant therapy (ADT). Pooled data from three randomized, double-blind, placebo-controlled studies assessing the efficacy of adjunctive aripiprazole to ADT in patients with major depressive disorder who had a minimal response [< 25% reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS)] to an 8-week prospective ADT. During the 6-week, double-blind adjunctive phase, response was defined as at least 50% reduction in the MADRS score and remission as at least 50% reduction in MADRS score and a MADRS score ≤ 10. Rates were examined using analysis of covariance and Cochran-Mantel-Haenszel tests. Kaplan-Meier curves were used to calculate time to response and remission. Of 1038 patients, 72% (n=746) exhibited a minimal response to ADT (ADT minimal responder). Time to response and remission were significantly shorter for ADT minimal responders receiving aripiprazole+ADT versus adjunctive placebo+ADT. ADT minimal responders on aripiprazole+ADT showed significantly greater improvements in MADRS score at endpoint compared with minimal responders on placebo+ADT (-10.3 vs. -6.5, P<0.0001). In addition, ADT minimal responders exhibited significantly higher response rates with aripiprazole+ADT than placebo+ADT (36 vs. 19%, respectively, P<0.0001) and higher remission rates (24 vs. 12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders.
|
Authors | James Craig Nelson, Michael E Thase, Elizabeth E Bellocchio, Linda M Rollin, James M Eudicone, Robert D McQuade, Ronald N Marcus, Robert M Berman, Ross A Baker |
Journal | International clinical psychopharmacology
(Int Clin Psychopharmacol)
Vol. 27
Issue 3
Pg. 125-33
(May 2012)
ISSN: 1473-5857 [Electronic] England |
PMID | 22466058
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antidepressive Agents
- Piperazines
- Quinolones
- Aripiprazole
|
Topics |
- Adult
- Antidepressive Agents
(adverse effects, therapeutic use)
- Aripiprazole
- Depressive Disorder, Major
(diagnosis, drug therapy, psychology)
- Drug Resistance
- Drug Therapy, Combination
- Evidence-Based Medicine
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Piperazines
(adverse effects, therapeutic use)
- Psychiatric Status Rating Scales
- Quinolones
(adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Remission Induction
- Time Factors
- Treatment Outcome
|